$2.70
+0.02 (+0.75%)
Open$2.68
Previous Close$2.68
Day High$2.73
Day Low$2.61
52W High$5.55
52W Low$2.71
Volume—
Avg Volume530.7K
Market Cap168.91M
P/E Ratio—
EPS$-1.81
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+1,620.0% upside
Current
$2.70
$2.70
Target
$46.44
$46.44
$29.94
$46.44 avg
$64.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 40.49M | 40.66M | 42.57M |
| Net Income | -120,051,824 | -108,513,248 | -129,666 |
| Profit Margin | -296.5% | -281.7% | -0.3% |
| EBITDA | -128,138,461 | -122,257,244 | -158,434 |
| Free Cash Flow | — | — | -114,389 |
| Rev Growth | -0.4% | -0.4% | +21.1% |
| Debt/Equity | — | — | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |